ONPATTRO

Product Overview

About ONPATTRO

ONPATTRO is a medicine that contains the active ingredient PATISIRAN (PATISIRAN SODIUM), which is used for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). This condition is characterized by the buildup of abnormal proteins called amyloids in various organs and tissues of the body, leading to their dysfunction. ONPATTRO is designed to specifically target and reduce the production of these abnormal proteins, thereby slowing down the progression of the disease.

Key Benefits & Uses

• Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)
• Reduces the production of abnormal transthyretin proteins
• May help to slow down the progression of the disease and improve symptoms

Active Ingredient & Action

PATISIRAN (PATISIRAN SODIUM) is a small interfering RNA (siRNA) that works by silencing the gene responsible for producing the transthyretin protein. By reducing the production of this protein, PATISIRAN (PATISIRAN SODIUM) helps to decrease the amount of abnormal amyloid proteins in the body, which can help to slow down the progression of hATTR amyloidosis.

Important Notes

ONPATTRO should only be used under the guidance of a healthcare professional. It is essential to follow the prescribed dosage and administration instructions carefully. Patients should also be monitored regularly for any potential side effects or changes in their condition. As with any medicine, it is crucial to discuss the benefits and risks of ONPATTRO with a healthcare provider before starting treatment.